Novartis (NVS)
(Delayed Data from NYSE)
$120.89 USD
+0.47 (0.39%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $120.83 -0.06 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Price, Consensus and EPS Surprise
NVS 120.89 +0.47(0.39%)
Will NVS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NVS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVS
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
NVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug
Medicare Releases Negotiated Prices on 10 Expensive Drugs
Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?
Other News for NVS
New Medicare drug price caps could help seniors save over $1,000 a year - AARP
Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
Novartis collaborating with Lindy Biosciences for multi-target drug delivery
Novartis twice-yearly Legvio in Phase III V-MONO study met primary endpoints